386 related articles for article (PubMed ID: 30604050)
1. Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure.
Kiss Á; Menus Á; Tóth K; Déri M; Sirok D; Gabri E; Belic A; Csukly G; Bitter I; Monostory K
Eur Arch Psychiatry Clin Neurosci; 2020 Feb; 270(1):71-82. PubMed ID: 30604050
[TBL] [Abstract][Full Text] [Related]
2. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
3. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
6. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
[TBL] [Abstract][Full Text] [Related]
7. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
8. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole.
Waade RB; Christensen H; Rudberg I; Refsum H; Hermann M
Ther Drug Monit; 2009 Apr; 31(2):233-8. PubMed ID: 19142178
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
Kirschbaum KM; Müller MJ; Malevani J; Mobascher A; Burchardt C; Piel M; Hiemke C
World J Biol Psychiatry; 2008; 9(3):212-8. PubMed ID: 17853280
[TBL] [Abstract][Full Text] [Related]
12. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5.
Okubo M; Morita S; Murayama N; Akimoto Y; Goto A; Yamazaki H
Hum Psychopharmacol; 2016 Mar; 31(2):93-102. PubMed ID: 26856541
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy.
Paulzen M; Haen E; Hiemke C; Stegmann B; Lammertz SE; Gründer G; Schoretsanitis G
Br J Clin Pharmacol; 2017 Aug; 83(8):1668-1675. PubMed ID: 28160505
[TBL] [Abstract][Full Text] [Related]
14. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.
Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122
[TBL] [Abstract][Full Text] [Related]
15. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
16. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.
Rafaniello C; Sessa M; Bernardi FF; Pozzi M; Cheli S; Cattaneo D; Baldelli S; Molteni M; Bernardini R; Rossi F; Clementi E; Bravaccio C; Radice S; Capuano A
Pharmacogenomics J; 2018 May; 18(3):422-430. PubMed ID: 28719598
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
Molden E; Lunde H; Lunder N; Refsum H
Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
[TBL] [Abstract][Full Text] [Related]
20. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites.
Chapron BD; Dinh JC; Toren PC; Gaedigk A; Leeder JS
Drug Metab Dispos; 2020 Nov; 48(11):1113-1120. PubMed ID: 32847865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
